Spark Therapeutics Inc. (ONCE)

45.08
NASDAQ : Health Technology
Prev Close 43.89
Day Low/High 43.52 / 45.93
52 Wk Low/High 34.53 / 96.59
Avg Volume 588.40K
Exchange NASDAQ
Shares Outstanding 37.22M
Market Cap 1.63B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Spark Therapeutics Further Expands Gene Therapy Expertise With Appointment Of Federico Mingozzi, Ph.D., As Chief Scientific Officer

Spark Therapeutics Further Expands Gene Therapy Expertise With Appointment Of Federico Mingozzi, Ph.D., As Chief Scientific Officer

Katherine A. High, M.D., will continue to serve as president and head of R&D

Spark Therapeutics Enters Into Licensing Agreement With Genethon

Spark Therapeutics Enters Into Licensing Agreement With Genethon

Includes exclusive worldwide rights to adeno-associated viral (AAV) gene therapy targeting the liver

Spark Therapeutics Is Ready to Catch Fire

Spark Therapeutics Is Ready to Catch Fire

Look for higher highs from this biotech play.

Spark Therapeutics Announces Publication Of Study Confirming Novel Test's Validity, Reliability And Ability To Detect Change In Functional Vision

Spark Therapeutics Announces Publication Of Study Confirming Novel Test's Validity, Reliability And Ability To Detect Change In Functional Vision

Multi-luminance mobility test (MLMT) was the primary endpoint in the Phase 3 trial for investigational LUXTURNA™ (voretigene neparvovec)

Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers

Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers

Illumina, Spark Therapeutics and Endo International were among the biotech stock movers in premarket trading on Aug. 2.

Spark Therapeutics Submits Marketing Authorization Application To European Medicines Agency For Investigational LUXTURNA™ (voretigene Neparvovec)

Spark Therapeutics Submits Marketing Authorization Application To European Medicines Agency For Investigational LUXTURNA™ (voretigene Neparvovec)

Potential for first gene therapy for a genetic disease to be approved in both the U.S. and EU

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Spark Therapeutics Announces Publication In The Lancet Of Pivotal Phase 3 Clinical Trial Data For Investigational Voretigene Neparvovec

Spark Therapeutics Announces Publication In The Lancet Of Pivotal Phase 3 Clinical Trial Data For Investigational Voretigene Neparvovec

Data show that 65 percent of participants demonstrated the maximal improvement in the clinical trial's primary endpoint, bilateral multi-luminance mobility testing (MLMT), at year one

First Week Of August 18th Options Trading For Spark Therapeutics (ONCE)

Investors in Spark Therapeutics Inc saw new options become available this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ONCE options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Spark Therapeutics Completes Rolling Biologics License Application Submission To FDA for Investigational Gene Therapy Voretigene Neparvovec

Voretigene neparvovec has the potential to be the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the U.S.

TheStreet Quant Rating: D (Sell)